Easton Pharmaceuticals Receives Final Changes & Nears Completion on Its Reg. A SEC Filing to Raise Up to $5,000,000 in Additi...
23 Abril 2014 - 7:28AM
Marketwired
Easton Pharmaceuticals Receives Final Changes and Nears Completion
on Its Reg. A SEC Filing to Raise Up to $5,000,000 in Additional
Committed Financing
TORONTO, ON--(Marketwired - Apr 23, 2014) - Easton
Pharmaceuticals Inc. (OTC: EAPH) announces it has received a final
draft of its Reg. A SEC document that is set to be filed with the
Securities and Exchange Commission later this week.
Easton's Delaware attorney has submitted final changes of the
filing to the company's board for review and comment. The company
anticipates submitting the filing with the Securities and Exchange
Commission sometime within the next few days or the end of this
week. The Reg. A filing is being supported by its current finance
partners who in the past 9 months have advanced Easton
Pharmaceuticals with $1,000,000 in financing. Once filed with the
SEC, the company should receive comments back, if any, within 10 to
20 days. The company's current financing partners have committed to
move forward, have asked for an exclusive and believe they will be
able to finance the full $5,000,000 over the next year.
The additional financings are required to fulfill most, if not
all initiatives which includes purchasing majority control of its
early stage cancer drug "Xilive," completing patent applications
and to move towards initiating early stage clinical trials in
certain select countries and jurisdictions. Funding is also
required to start manufacturing, marketing and sales of its OTC
"Viorra" product and its other OTC line of products which are all
at different stages of development, as well as to move towards
finalizing on its medical marijuana initiatives which have
advanced.
Easton Pharmaceuticals believes its efforts in the medical
marijuana industry may soon result in a positive development that
will allow the company to enter the medical marijuana industry as a
possible grower and seller of medical marijuana and other types of
marijuana products, which will include future growth and expansion
abilities. This may initially involve certain jurisdictions of the
United States, Canada and possibly both with adequate
financing.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company
involved in various pharmaceutical sectors that owns, designs,
develops, and markets topically-delivered drugs and therapeutic /
cosmetic healthcare products, focused on cancer and other health
issues related towards male and female sexual dysfunction, wound
healing, pain, motion sickness, scar and stretch marks, cellulite,
varicose veins and other conditions. The company is also
endeavoring to enter other potentially lucrative industries such as
medical marijuana. The company's gel formulation is thought to be
an innovative and unique transdermal delivery system. Easton
Pharmaceuticals' product "VIORRA" is an over-the-counter,
topical daily use product and aid for the treatment to restore and
improve vaginal moisture and elasticity which is believed to have a
positive effect on women's sexual desire and arousal, FSAD (Female
Sexual Arousal Disorder); the world market for these female
conditions is conservatively estimated to be in the billions.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
Safe Harbor
This news release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(The "Act"). In particular, when used in the preceding of
discussion, the words "anticipate," "pleased," "plan," "confident
that," "believe," "expect," "possible" or "intent to" and similar
conditional expressions are intended to identify forward-looking
statements within the meaning of the Act and are subject to the
safe harbor created by the Act. Such statements are subject to
certain risks and uncertainties and actual results could differ
materially from those expressed in any of the forward-looking
statements. Any investment could be classified as speculative and
risky. Such risks and uncertainties include, but are not limited
to, market conditions, general acceptance of the company's products
and technologies, competitive factors, the ability to successfully
complete additional or adequate financing, government approvals or
changes to proposed laws and other risks and uncertainties further
stated in the company's financial reports and filings.
Contact: Carla Pepe Kent Deuters Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291 Tel: +1(347) 284-0192 Email:
info@eastonpharmaceuticalsinc.com Email:
legal@eastonpharmaceuticalsinc.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024